Soleus Capital Management, L.P. Zymeworks Inc. Transaction History

Soleus Capital Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$29.83 - $56.81 $675,082 - $1.29 Million	-22,631 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $2.61 Million - $3.66 Million	-66,602 Reduced 74.64%	22,631 $1.07 Million
Q3 2020 Nov 13, 2020	SELL	$29.21 - $46.58 $9.69 Million - $15.4 Million	-331,603 Reduced 78.8%	89,233 $4.16 Million
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $12.1 Million - $14.4 Million	359,308 Added 583.97%	420,836 $15.2 Million
Q1 2020 May 15, 2020	BUY	$24.28 - $49.8 $942,743 - $1.93 Million	38,828 Added 171.05%	61,528 $2.18 Million
Q4 2019 Feb 14, 2020	BUY	$24.84 - $45.46 $563,868 - $1.03 Million	22,700 New	22,700 $1.03 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.